FDA Approves DESOXIMETASONE — Saptalis Pharmaceuticals, LLC.

# FDA Approves Saptalis Pharmaceuticals' Generic Desoximetasone Topical Treatment Saptalis Pharmaceuticals, LLC has received FDA approval for its generic desoximetasone topical formulation (ANDA203234), expanding the competitive landscape in the corticosteroid market and potentially increasing access to this dermatological treatment while reducing patient costs through generic pricing.